TETEC AG’S CDMO business is now Octane CDMO, a global operation with automation expertise

Kingston, Ontario, January 2, 2025 – The Octane Medical Group is pleased to announce that the contract development and manufacturing arm of its German subsidiary TETEC AG is now Octane CDMO, an expanded operation with the know-how, years of experience, technology, systems and international network to drive complex, personalized cell therapies from concept to commercialization.

“As the first CDMO to develop and commercialize two in-house ATMPs, Octane CDMO is uniquely positioned to help other ATMP developers safeguard the success of their innovation,” says Timothy Smith, CEO and co-founder of Octane, a global leader in regenerative medicine with the most advanced technologies in cell therapy, spinal implants, medical imaging and bioelectricity. “Our team of seasoned scientists, regulatory experts and manufacturing specialists has a proven track record of bringing cell therapy innovations to market, and to patients around the world.”

Another important differentiator for Octane CDMO is its longstanding expertise in process automation – a strategic advantage that ATMP developers are increasingly seeking. Using third-party technology or Octane’s own Cocoon automated bioreactor, Octane CDMO works with ATMP developers to introduce automation early in their development and commercialization journey. This accelerates model translation, eliminates the need to revalidate manual processes, and leads to economies of scale across development and production.

“We are agile. Drawing on our expertise and tool sets, we will help you find the ideal solution to optimize your process to accelerate and ensure  your vision,” says Detlef Schumann, CEO at Octane CDMO. “Our solutions include translating your processes into the GMP environment, manufacturing your clinical specimen,  setting up and coordinating clinical trials, obtaining regulatory approvals and helping you to register your ATMP – all delivered through a proven, methodical approach designed to minimize your risk and ensure your success.”

Beyond its scientific, regulatory and production expertise, Octane CDMO offers greater cell product development and manufacturing capacity. ATMP developers who partner with Octane CDMO get access to more than 11,150 square metres (120,000 square feet) of state-of-the-art product development and manufacturing facilities in Canada, Germany and the United States. These facilities are ISO- and GMP-certified, and can run multiple ATMP and medical device projects simultaneously to deliver on a global scale.

The launch of Octane CDMO is the latest milestone in Octane’s global expansion strategy, which includes the acquisition last year of TETEC and Aesculap Biologics LLC in Breinigsville, Pennsylvania, U.S.A. These acquisitions advanced Octane’s goal of bringing new regenerative medicine technologies to patients around the world.

This goal is further amplified with Octane CDMO’s unique abilities and expanded capacity to help ATMP developers around the world bring their innovations to international markets.

“We have lived what it takes to drive complex, personalized cell therapies from concept to profitable commercialization,” says Smith. “We look forward to helping even more ATMP innovators advance with confidence through every stage of their development and commercialization journey.”

ABOUT OCTANE MEDICAL GROUP

Headquartered in Ontario, Canada with locations in the United States and Europe, Octane is a global group of companies with the most advanced bioprocesses, biomaterials and bioreactors for regenerative medicine. We power transformative healthcare with game-changing technologies that we develop and turn into proof-of-concept platforms in our basecamp company, Octane Innovations Inc. These innovations are advanced into production within our market-specific Octane ventures, for global commercialization with our industry partners. Today, our Octane ventures include Octane Clinical Systems, Octane Orthobiologics, Octane Exo, Octane Biotech and Octane Biotherapeutics (BioTx).

 At Octane, our goal is to make regenerative medicine the standard of care. For more information, visit www.octaneco.com.